DK1309627T3 - Immunoterapi for kronisk myelocytisk leukæmi med nögent anti-NCA-90-antistof - Google Patents

Immunoterapi for kronisk myelocytisk leukæmi med nögent anti-NCA-90-antistof

Info

Publication number
DK1309627T3
DK1309627T3 DK01957479T DK01957479T DK1309627T3 DK 1309627 T3 DK1309627 T3 DK 1309627T3 DK 01957479 T DK01957479 T DK 01957479T DK 01957479 T DK01957479 T DK 01957479T DK 1309627 T3 DK1309627 T3 DK 1309627T3
Authority
DK
Denmark
Prior art keywords
immunotherapy
myelocytic leukemia
chronic myelocytic
nca
nude
Prior art date
Application number
DK01957479T
Other languages
English (en)
Inventor
David M Goldenberg
Hans J Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DK1309627T3 publication Critical patent/DK1309627T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01957479T 2000-08-08 2001-08-08 Immunoterapi for kronisk myelocytisk leukæmi med nögent anti-NCA-90-antistof DK1309627T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22369800P 2000-08-08 2000-08-08
PCT/US2001/024691 WO2002012347A1 (en) 2000-08-08 2001-08-08 Immunotherapy for chronic myelocytic leukemia

Publications (1)

Publication Number Publication Date
DK1309627T3 true DK1309627T3 (da) 2009-12-21

Family

ID=22837639

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01957479T DK1309627T3 (da) 2000-08-08 2001-08-08 Immunoterapi for kronisk myelocytisk leukæmi med nögent anti-NCA-90-antistof

Country Status (10)

Country Link
US (2) US6759045B2 (da)
EP (1) EP1309627B1 (da)
JP (1) JP3888971B2 (da)
CN (1) CN1468259A (da)
AT (1) ATE444309T1 (da)
AU (1) AU7921701A (da)
CA (1) CA2418014C (da)
DE (1) DE60140063D1 (da)
DK (1) DK1309627T3 (da)
WO (1) WO2002012347A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU2001290801A1 (en) * 2000-09-12 2002-03-26 Zycos Inc. Peptide epitopes recognized by antigen specific cd4+ t lymphocytes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002360525A1 (en) * 2001-12-06 2003-06-23 University Of Florida Targeting leukemia cells
CA2481304A1 (en) * 2002-03-27 2003-10-09 Patrick Hwu Method for treating cancer in humans
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
AU2002348178A1 (en) * 2002-11-06 2004-06-03 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
BR0316101A (pt) * 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
NZ543635A (en) * 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
ATE486611T1 (de) 2003-12-04 2010-11-15 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
EP1732650A4 (en) * 2004-03-27 2008-06-11 Univ Arizona COMPOSITION AND METHOD FOR CANCER TREATMENT
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
US20060234959A1 (en) * 2005-04-14 2006-10-19 Advanced Photodynamic Technologies, Inc. Photodynamic therapy utilizing multiple duty cycle light modulation
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
EP1962913B1 (en) * 2005-11-30 2013-12-04 Therapharm GmbH Radioimmunoconjugate for human cd66 for the treatment of multiple myeloma
EP1988901B1 (en) 2006-02-27 2020-01-29 Gal Markel Ceacam based antibacterial agents
BRPI0710650A2 (pt) * 2006-04-13 2011-08-23 Medical And Biological Laboratories Co., Ltd células parceiras de fusão
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
US6491917B1 (en) 1998-07-31 2002-12-10 Stemcell Technologies Inc. Antibody composition for debulking blood and bone marrow samples from CML patients

Also Published As

Publication number Publication date
JP3888971B2 (ja) 2007-03-07
US20040213796A1 (en) 2004-10-28
US6759045B2 (en) 2004-07-06
ATE444309T1 (de) 2009-10-15
AU2001279217C1 (en) 2002-02-18
CA2418014A1 (en) 2002-02-14
WO2002012347A1 (en) 2002-02-14
EP1309627A1 (en) 2003-05-14
AU7921701A (en) 2002-02-18
US7323168B2 (en) 2008-01-29
US20020022031A1 (en) 2002-02-21
EP1309627B1 (en) 2009-09-30
CN1468259A (zh) 2004-01-14
CA2418014C (en) 2014-01-21
JP2004505994A (ja) 2004-02-26
DE60140063D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
DK1309627T3 (da) Immunoterapi for kronisk myelocytisk leukæmi med nögent anti-NCA-90-antistof
CY1120658T1 (el) Αντισωματα ως προς opgl
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
BRPI0012196B8 (pt) artigo industrializado
EP2269656A3 (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
DE60334247D1 (de) Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
IL214325A (en) Antibody against cmet, a drug that includes and uses it
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
SG136804A1 (en) Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
SG147294A1 (en) Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy.
CL2012000519A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07).
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.